Monitor FDA response to the IDE application; stock may be volatile on updates. Look for subsequent clinical trial enrollment announcements as the next catalyst.
Price Chart
Executive Summary
Glucotrack announced submission of an IDE application to the FDA to initiate a US clinical study for its fully implantable continuous blood glucose monitor. This is a significant regulatory milestone for the micro-cap company, moving its CBGM technology closer to clinical evaluation, but does not guarantee approval or commercial launch.
Key Facts
- Glucotrack submitted an IDE application to the FDA for its fully implantable CBGM.
- The IDE submission allows the company to pursue a US clinical study pending FDA approval.
- The CBGM is designed for 3-year sensor longevity with no on-body wearable and minimal calibration.
- The company has a market cap of approximately $2M and is pre-revenue.
Financial Impact
Not quantifiable from filing; no financial terms disclosed.
Risk Factors
- FDA may not approve the IDE, delaying or halting clinical trials.
- The company may need to raise additional capital to fund clinical studies.
- Competition from established CGM players like Dexcom and Abbott.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3290388 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 3d ago | 8-K | $0.6081 | awaiting T+60 | — | — |
Oct 19, 2026 7d ago | 8-K | $0.6511 | awaiting T+60 | — | — |
Oct 13, 2026 12d ago | S-1/A | $0.8873 | awaiting T+60 | — | — |
Oct 13, 2026 13d ago | 425 | $0.8873 | awaiting T+60 | — | — |
Sep 28, 2026 27d ago | 8-K | $1.74 | awaiting T+60 | — | — |
Sep 24, 2026 4w ago | 424B5 | $1.82 | awaiting T+60 | — | — |
Sep 24, 2026 4w ago | 8-K | $1.82 | awaiting T+60 | — | — |
Sep 23, 2026 4w ago | 425 | $2.03 | awaiting T+60 | — | — |
Sep 23, 2026 4w ago | 8-K | $2.03 | awaiting T+60 | — | — |
Sep 18, 2026 5w ago | 8-K | $2.30 | awaiting T+60 | — | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers